<p>(a) The active osteoclast after multi-dose pamidronate administration. (b) The bone volume after multi-dose pamidronate administration. (c) The MM-cell density after multi-dose pamidronate administration. Blue: the intact model; Black: the blocked model.</p
BACKGROUND: Increased osteolysis usually accompanies sclerotic bone metastases from prostate cancer....
Background Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skelet...
textabstractA previously established mechanism-based disease systems model for osteoporosis that is ...
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
PURPOSE: Bisphosphonates have been used to treat osteoporosis for more than ten years. However, comp...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
<p>(a) The active osteoclast using the identified denosumab regimes. (b) The bone volume using the i...
Background and Aim: For the treatment of osteoporosis, bisphosphonates are commonly used as oral or ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
2011-08-01Alendronate is the most frequently prescribed drug for the treatment and prevention of low...
Purpose: We investigated the effects of the long-term administration of pamidronate on long bone str...
Alendronate is the most widely used drug for postmenopausal osteoporosis (PMO). It inhibits bone res...
<p>(a) Changes in osteoblast density after therapies; (b) Changes in osteoclast density after therap...
PURPOSE: To compare increment of bone mineral density (BMD) with pamidronate, zoledronate and the is...
BACKGROUND: Increased osteolysis usually accompanies sclerotic bone metastases from prostate cancer....
Background Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skelet...
textabstractA previously established mechanism-based disease systems model for osteoporosis that is ...
<p>(a) The active osteoclasts after multi–dose administration every 30 days. (b) The MM-cell density...
PURPOSE: Bisphosphonates have been used to treat osteoporosis for more than ten years. However, comp...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
<p>(a) The active osteoclast using the identified denosumab regimes. (b) The bone volume using the i...
Background and Aim: For the treatment of osteoporosis, bisphosphonates are commonly used as oral or ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
It is unclear whether the new anti-catabolic agent denosumab represents a viable alternative to the ...
2011-08-01Alendronate is the most frequently prescribed drug for the treatment and prevention of low...
Purpose: We investigated the effects of the long-term administration of pamidronate on long bone str...
Alendronate is the most widely used drug for postmenopausal osteoporosis (PMO). It inhibits bone res...
<p>(a) Changes in osteoblast density after therapies; (b) Changes in osteoclast density after therap...
PURPOSE: To compare increment of bone mineral density (BMD) with pamidronate, zoledronate and the is...
BACKGROUND: Increased osteolysis usually accompanies sclerotic bone metastases from prostate cancer....
Background Compared with placebo, prophylactic treatment with bisphosphonates reduces risk of skelet...
textabstractA previously established mechanism-based disease systems model for osteoporosis that is ...